Search Within

Igor Odintsov

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (15)
  2. Meeting Abstract (5)
  3. Editorial (1)
Groups
  1. Department of Pathology and Laboratory Medicine (21)
  2. GSK Faculty (21)
  3. Human Oncology and Pathogenesis Program (21)
  4. Sloan Kettering Institute Postdocs (21)
  5. Tow Center for Developmental Oncology (TCDO) (21)
  6. Department of Medicine (11)

More Groups

People
  1. Marc Ladanyi (21)
  2. Romel Somwar (21)
  3. Elisa De Stanchina (15)
  4. Inna Khodos (13)
  5. Marissa Mattar (13)
  6. Jo Weng Allan Lui (10)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (6)
  4. 2021 (8)
  5. 2020 (2)
  6. 2019 (1)
Publications
  1. Cancer Research (4)
  2. Journal of Thoracic Oncology (3)
  3. Clinical Cancer Research (2)
  4. Disease Models & Mechanisms (2)
  5. JCO Precision Oncology (2)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. American Association for Cancer Research (8)
  2. Elsevier Inc. (4)
  3. American Society of Clinical Oncology (3)
  4. Company of Biologists (2)
  5. Cold Spring Harbor Laboratory Press (1)
  6. Nature Research (1)

More Publishers

Results (21)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MYC promotes tyrosine kinase inhibitor resistance in ROS1 fusion positive lung cancers
    Meeting Abstract

    Iyer, S. R.; Odintsov, I.; Schoenfeld, A. J.; Sato, H.; Siau, E.; Drilon, A.; Riely, G. J.; Somwar, R.; Ladanyi, M.; Davare, M. A.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions
    Meeting Abstract

    Odintsov, I.; Lui, A. J.; Bloom, P. R.; Vojnic, M.; Leland, S.; Ladanyi, M.; Somwar, R.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • The HER2xHER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
    Meeting Abstract

    Odintsov, I.; Khodos, I.; Espinosa-Cotton, M.; Lui, A. J.; Mattar, M.; Schram, A. M.; Schackmann, R. C.; Lammerts van Bueren, J.; Geuijen, C. A.; de Stanchina, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers
    Journal Article

    Odintsov, I.; Mattar, M. S.; Lui, A. J. W.; Offin, M.; Kurzatkowski, C.; Delasos, L.; Khodos, I.; Asher, M.; Daly, R. M.; Rekhtman, N.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • The anti-HER3 mAb seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions
    Journal Article

    Odintsov, I.; Lui, A. J. W.; Sisso, W. J.; Gladstone, E.; Liu, Z.; Delasos, L.; Kurth, R. I.; Sisso, E. M.; Vojnic, M.; Khodos, I.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Therapeutic potential of NTRK3 inhibition in desmoplastic small round cell tumor
    Journal Article

    Ogura, K.; Somwar, R.; Hmeljak, J.; Magnan, H.; Benayed, R.; Momeni Boroujeni, A.; Bowman, A. S.; Mattar, M. S.; Khodos, I.; de Stanchina, E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • RET inhibition in novel patient-derived models of RET fusion-positive lung adenocarcinoma reveals a role for MYC upregulation
    Journal Article

    Hayashi, T.; Odintsov, I.; Smith, R. S.; Ishizawa, K.; Liu, A. J. W.; Delasos, L.; Kurzatkowski, C.; Tai, H.; Gladstone, E.; Vojnic, M.; more...
    Disease Models & Mechanisms (2021)

    Fulltext@MSK | Save
  • ROS1 at the crossroads of clinical oncology, molecular diagnostics, and drug development
    Editorial

    Odintsov, I.; Somwar, R.; Ladanyi, M.; Drilon, A.
    JCO Oncology Practice (2021)

    Fulltext@MSK | Save
  • NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
    Journal Article

    Somwar, R.; Hofmann, N. E.; Smith, B.; Odintsov, I.; Vojnic, M.; Linkov, I.; Tam, A.; Khodos, I.; Mattar, M. S.; de Stanchina, E.; more...
    Communications Biology (2020)

    Fulltext@MSK | Save
  • The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
    Meeting Abstract

    Odintsov, I.; Gladstone, E.; Sisso, W. J.; Delasos, L.; Lui, A. J. W.; Sisso, E. M.; Vojnic, M.; Khodos, I.; Mattar, M. S.; de Stanchina, E.; more...
    European Journal of Cancer (2020)

    Fulltext@MSK | Save